Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
TR2-C52H7 | Cynomolgus | Cynomolgus TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
TR2-M52H5 | Mouse | Mouse TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
TR2-H82E6 | Human | Biotinylated Human TRAIL R2 / DR5 / TNFRSF10B Protein, Avitag™,His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
TR2-H5255 | Human | Human TRAIL R2 / DR5 / TNFRSF10B Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
TR2-H5229 | Human | Human TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
Loaded Human TRAIL R2, Fc Tag (Cat. No. TR2-H5255) on AHC Biosensor, can bind Human TRAIL, His Tag with an affinity constant of 0.146 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Immobilized Human TNFSF10 at 2 μg/mL (100 μL/well) can bind Mouse TRAIL R2, His Tag (Cat. No. TR2-M52H5) with a linear range of 0.039-0.625 μg/mL (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Oba-01 | Oba-01; Oba01 | Phase 1 Clinical | Yantai Heyuanaidisi Biomedical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma) | CTB-006 | Phase 1 Clinical | Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi, Lonn Ryonn Pharma Ltd | Solid tumours | Details |
Anti-DR5 CAR-T cell therapy (Shenzhen BinDeBio) | Phase 2 Clinical | Dehe Biotech Co Ltd | Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Glioma; Carcinoma, Hepatocellular | Details | |
IGM-8444 | Phase 1 Clinical | Igm Biosciences Inc | Chondrosarcoma; Solid tumours; Stomach Neoplasms; Sarcoma; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung | Details | |
INBRX-109 | JCT-205; INBRX-109 | Phase 1 Clinical | Inhibrx | Adenocarcinoma | Details |
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech) | Phase 3 Clinical | Shenzhen Sinobioway Xinpeng Biomedicine Co Ltd | Neoplasms | Details | |
Dulanermin (Shanghai GeBaiDe) | Phase 3 Clinical | Shanghai Gebaide Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
BI-905711 | BI-905711 | Phase 1 Clinical | Boehringer Ingelheim Gmbh | Pancreatic Neoplasms; Cholangiocarcinoma; Gastrointestinal Neoplasms | Details |
This web search service is supported by Google Inc.